Rapamycin Inhibits Activator Protein-1 But Not Nuclear Factor-κB Activity of Mature Bone Marrow-Derived Dendritic Cells

Wang, G.-Y.; Chen, G.-H.; Li, Heng; Huang, Yong; Zhang, Mengjie; Jiang, Nan; Chen, W.-J.

doi:10.1016/j.transproceed.2010.04.013

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although a relationship between mTOR and NF-κB has been alluded to in the literature, studies have demonstrated varying results regarding the effect of sirolimus on NF-κB signaling [ 52 ], [ 53 ], [ 54 ], and it appears that the modulatory activities may differ according to cell type and pathological state [ 55 ]. While these studies indicate that Akt acts as a key intersection point between the mTOR and NF-κB pathways, it is unclear whether NF-κB is under the control of mTOR or vice versa.…”

Section: Discussionmentioning

confidence: 99%

Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease

Schwensen

Foster

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

The disease-modifying effects of target of rapamycin complex 1 (TORC1) inhibitors during different stages of polycystic kidney disease (PKD) are not well defined. In this study, male Lewis Polycystic Kidney Disease (LPK) rats (a genetic ortholog of human NPHP9, phenotypically characterised by diffuse distal nephron cystic growth) and Lewis controls received either vehicle (V) or sirolimus (S, 0.2 mg/kg by intraperitoneal injection 5 days per week) during the early (postnatal weeks 3 to 10) or late stages of disease (weeks 10 to 20). In early-stage disease, sirolimus reduced kidney enlargement (by 63%), slowed the rate of increase in total kidney volume (TKV) in serial MRI by 78.2% (LPK+V: 132.3±59.7 vs. LPK+S: 28.8±12.0% per week) but only partly reduced the percentage renal cyst area (by 19%) and did not affect the decline in endogenous creatinine clearance (CrCl) in LPK rats. In late-stage disease, sirolimus reduced kidney enlargement (by 22%) and the rate of increase in TKV by 71.8% (LPK+V: 13.1±6.6 vs. LPK+S: 3.7±3.7% per week) but the percentage renal cyst area was unaltered, and the CrCl only marginally better. Sirolimus reduced renal TORC1 activation but not TORC2, NF-κB DNA binding activity, CCL2 or TNFα expression, and abnormalities in cilia ultrastructure, hypertension and cardiac disease were also not improved. Thus, the relative treatment efficacy of TORC1 inhibition on kidney enlargement was consistent at all disease stages, but the absolute effect was determined by the timing of drug initiation. Furthermore, cystic microarchitecture, renal function and cardiac disease remain abnormal with TORC1 inhibition, indicating that additional approaches to normalise cellular dedifferentiation, inflammation and hypertension are required to completely arrest the progression of PKDs.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease

Schwensen

Foster

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The generation of bone marrow‐derived DCs has been described previously 12,13 . In brief, bone marrow cells were depleted of red blood cells with hypotonic buffered tris‐ammonium chloride (0.83%, pH 7.21).…”

Section: Methodsmentioning

confidence: 99%

Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4⁺CD25⁺Foxp3⁺ regulatory T cell expansion

Wang

Yang

et al. 2011

Hepatology Research

View full text Add to dashboard Cite

show abstract

Aqueous extract of Passiflora alata leaves modulates in vitro the indoleamine 2,3-dioxygenase (IDO) and CD86 expression in bone marrow-derived professional antigen-presenting cells polarizing NOD mice T cells to a Treg profile

2022

View full text Add to dashboard Cite

Rapamycin Inhibits Activator Protein-1 But Not Nuclear Factor-κB Activity of Mature Bone Marrow-Derived Dendritic Cells

Cited by 4 publications

References 20 publications

Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease

Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease

Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4⁺CD25⁺Foxp3⁺ regulatory T cell expansion

Aqueous extract of Passiflora alata leaves modulates in vitro the indoleamine 2,3-dioxygenase (IDO) and CD86 expression in bone marrow-derived professional antigen-presenting cells polarizing NOD mice T cells to a Treg profile

Contact Info

Product

Resources

About

Rapamycin Inhibits Activator Protein-1 But Not Nuclear Factor-κB Activity of Mature Bone Marrow-Derived Dendritic Cells

Cited by 4 publications

References 20 publications

Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease

Effects of TORC1 Inhibition during the Early and Established Phases of Polycystic Kidney Disease

Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4+CD25+Foxp3+ regulatory T cell expansion

Aqueous extract of Passiflora alata leaves modulates in vitro the indoleamine 2,3-dioxygenase (IDO) and CD86 expression in bone marrow-derived professional antigen-presenting cells polarizing NOD mice T cells to a Treg profile

Contact Info

Product

Resources

About

Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4⁺CD25⁺Foxp3⁺ regulatory T cell expansion